text:
Projects - Project Summaries - Requests - Links - Main
Live-Action Film Projects
Cat's Eye
Right when I saw the new costumes, I knew I had to sub this ^_^. Actually, it's pretty cool. It stars sugoi kawaii Fujiwara Norika, an on-fire Inamori Izumi, and magically babe-licious Uchida Yuki. These three sisters make up Cat's Eye, who are notorious art thieves. But, they're not evil though ^_^. They're trying to find their missing father by stealing back his artworks in the hope of finding some clue to his whereabouts. They also happen to run a cafe named Cat's Eye. And to complicate things the detective assigned to catching them happens to hang out at Cat's Eye all the time because he's dating the middle sister, Hitomi. But, he has no idea that she's one of the girls that he's trying to arrest. I haven't seen the anime version, but I like the live-action one for sure.
Hana Yori Dango
This movie also stars Uchida Yuki in the title role ^_^. She's a poor girl that gets into a prestigious private school. While she's there, she runs into F4 (four guys from very prominent families) and gets into trouble with them. They start playing pranks on her and making her life hell, but she fights back. Somewhere along the way, the leader of F4 starts falling for her, but she actually has a crush on one of the other members. Then there's a beautiful girl that she has to try and compete with to get his attention. And this happens, and that happens. And you know? You have to watch the movie to see what I'm talking about ^_^. Actually if you've read the manga or seen the anime then you already know.
Tokimeki Memorial
It's the last summer of Suzuki Akihiko's high school life. He wants it to be a memorable one and he's really in love with the idea of being in love. He manages to get a summer job running an ocean-side cafe with 4 of the prettiest girls at his school: Natsumi, Namie, Nishio, and Komugi. Oh, and some guy named Kosuke is there too, but I didn't pay attention to that part. Anyway, it's really humorous and poignant. And does his dream girl, Shiori, show up? You'll see ^_^
That's Cunning!
This is the only title that isn't available for distribution. But, if you're ever in the Los Angeles area, look me up and maybe you can watch it ^_^. It's a comedy starring my favorite girl, Amuro Namie ^_~. Namie-chan is attending a college where there's an evil professor that wants his students to fail so he can build some hotel on the site where the Sigma House stands. How do the students fight back? They CHEAT!! If you're a college student, you HAVE to see this movie. It's hilarious! And the ideas they come up with to cheat are side-splittingly funny. All the funky characters just kept me laughing the whole time. And with Namie-chan in it, this movie kicks ass ^_^
For those wondering why we are not distributing this project, please read the following exchange:
Here's my reply to someone else who asked about the movie:
>why do you list "that's cunning" if you aren't going to accept any requests
>for it? that is just plain CRUEL to some of us who love namie, but speak
>little or no japanese. btw, these questions were not meant to offend you or
>anyone on your staff. they have just been bothering me. thanx for your
>time, jun.
We list That's Cunning because it's one of our projects and we'd
like people to know about it. We aren't trying to be cruel by keeping
it off distribution lists. It's just that I really like Namie too,
and don't want somebody taking a copy of what we worked so hard
on and selling it to people for $20. As you know, boku no Namie-chan
is very popular so people would be willing to pay it. We've been
having private showings of That's Cunning at Anime Expo and here
in L.A. for some Namie fans. I'm sorry if you don't live near L.A.,
so you can come see it, but the only way to make sure that That's
Cunning doesn't fall into the wrong hands is to keep it off distribution lists.
I hope I've sufficiently answered your questions. If not, then
feel free to email me back. We take no offense when people are
genuinely curious as to how our policies work.
Joey, Team Abcb
All characters are copyright their respective creators.
Back to Main Project Summaries Page
For sponsorship info, click here -----> Sponsorship Page
Send email to Joey at firstname.lastname@example.com


text:
'SNL' Isn't Done With The Trump Jokes YetNovember 20, 2016
If you've been watching "SNL" this season, you know the drill by now: The show opens with a sketch primarily focused on making fun of President-elect Donald Trump. It's been a recurring feature of the show, and a popular one.
But Trump seems pretty over it.
I watched parts of @nbcsnl Saturday Night Live last night. It is a totally one-sided, biased show - nothing funny at all. Equal time for us?— Donald J. Trump (@realDonaldTrump) November 20, 2016
... Awkward.
It didn't help that the show made fun of just about everything that's been happening with the Trump campaign as he transitions to the White House. The sketch covered David Duke, the former Ku Klux Klan leader who keeps announcing his support for Trump, that awkward meeting with Mitt Romney and the whole Mike Pence "Hamilton" fiasco. Oh, and they had Trump ask, "Siri, how do I kill ISIS?" before realizing he was talking to a BlackBerry. That's a lot of shade to throw in a six-minute sketch.

subset: commoncrawl


text:
More News
City of St. Augustine Attorney Isabelle Lopez spoke on Thursday, November 2, at the Florida Coastal Law Conference in Tampa. Ms. Lopez, who co-wrote "Sea level rise adaptation: Funding sources" with Abby Corbett and Jason Koslowe (Stearns Weaver Miller, P.A.), discussed innovative ways to use funding sources to construct infrastructure that will be more resilient to sea level rise. The presentation was delivered to attorneys and government officials.
Ms. Lopez has been City Attorney for the City of St. Augustine since her appointment in 2014, following her time as Assistant City Attorney, since 2011. Prior to her positions with the city she was a partner at two statewide law firms, and worked with the Florida Department of Transportation and St. Johns County. She is a graduate of McGill University and received her Juris Doctor from the University of Florida.


text:
- Commentary
- Open Access
Nociceptors in cardiovascular functions: complex interplay as a result of cyclooxygenase inhibition
- Louis S Premkumar1Email author and
- Manish Raisinghani1
© Premkumar and Raisinghani; licensee BioMed Central Ltd. 2006
- Received: 10 August 2006
- Accepted: 17 August 2006
- Published: 17 August 2006
Prostaglandins (PGs) are requisite components of inflammatory pain as indicated by the efficacy of cyclooxygenase 1/2 (COX1/2) inhibitors. PGs do not activate nociceptive ion channels directly, but sensitize them by downstream mechanisms linked to G-protein coupled receptors. Antiinflammatory effects are purported to arise from inhibition of synthesis and/or release of proinflammatory agents. Release of these agents from peripheral and central terminals of sensory neurons modulates nociceptive input from the periphery and synaptic transmission at the first sensory synapse, respectively. Heart and blood vessels are densely innervated by sensory nerve endings that express chemo-, mechano-, and thermo-sensitive receptors. Activation of these receptors mediates synthesis and/or release of vasoactive agents by virtue of their Ca2+permeability. In this article, we discuss that inhibition of COX2 reduces PG synthesis and renders beneficial effects by preventing sensitization of nociceptors, but at the same time, it might contribute to deleterious cardiovascular effects by compromising the synthesis and/or release of vasoactive agents.
- Arachidonic Acid
- Capsaicin
- Vasoactive Intestinal Peptide
- Fatty Acid Amide Hydrolase
- Vasoactive Agent
Synthesis and functions of arachidonic acid and its metabolites
Arachidonic acid (AA) and its metabolites are involved in several important cardiovascular functions. In this article, we address the adverse cardiovascular effects that arise as a result of block of PG mediated modulation of nociceptive ion channels. AA is produced from membrane phospholipids by phospholipase A2 (PLA2), a calcium-dependent enzyme, which is activated by proinflammatory agents and shear stress exerted on the vessel wall. Activation of phospholipase C (PLC) hydrolyzes phosphatidyl inositol 4, 5 bisphosphate (PIP2) to inositol 1, 4, 5 trisphosphate (IP3) and diacyl glycerol (DAG). DAG activates protein kinase C (PKC) and DAG lipase, activation of DAG lipase can in turn produce AA. Activation of phospholipase D produces anandamide, which can subsequently be converted to AA by fatty acid amide hydrolase [1].
AA is metabolized via cyclooxygenase (COX1/2), lipoxygenase (5, 12, 15, LOX) and cytochrome P450 (CYP) pathways. COX1 is constitutively active, whereas COX2 is inducible, except in the kidneys and in some parts of central nervous system, where it is expressed constitutively [2]. Cyclooxygenase activation produces prostaglandin H2 (PGH2), which is subsequently metabolized to PGD2, PGE2, PGF2α, PGI2 and thromboxane A2 (TxA2) [1].
Cardiovascular functions of AA and its metabolites
AA Metabolite
Receptor subtypes
Secondary messenger mechanisms
Tissue distribution of the receptors
Cardiovascular functions of AA metabolites
Gs (DP1, 2), Gi, Gq, MAPK (DP2)
Leptomeninges, Langerhan cells, Goblet and columnar cells in GI tract, Eosinophils for DP1, All tissues for DP2
Vasodilation, Vasoconstriction, Platelet deaggregation
1, 12
Gs, Gi, Gq
Kidney, Lung and Stomach for EP1, EP2 expressed in response to LPS and gonadotrophins, EP3 and 4 in all tissues
Vasodilation, Vasoconstriction, Maintain renal blood flow and GFR, Vascular smooth muscle mitogenesis
1, 12, 15
Gs (predominant), Gi, Gq
Neurons, (primarily DRGs), Endothelial cells, Vascular smooth muscle cells, Kidney, Thymus, Spleen and Megakaryocytes
Vasodilation, Inhibit platelet aggregation, Inhibit TXA2-induced vascular proliferation
1, 12, 21, 58
Gq, EGFR
Corpus luteum, Kidney, Heart, Lung and Stomach
Vasoconstriction, Mitogenesis in heart, Inflammatory tachycardia, Renal functions
1, 12
Gq, Gs, Gi, Gh, G12
Kidney, Heart, Lungs, Platelets and Immune cells
Platelet aggregation, Vasoconstriction, Inflammatory tachycardia
1, 12, 58
Gq, Tyrosine kinase, Increased conductance of L-type Ca2+ channels, Inhibition of Na+-K+-2Cl cotransporter
Renal and cerebral artery contraction, Antagonize EDHF mediated vasorelaxation, Myogenic constriction, Regulate renal functions
1, 54
Leukotrienes (LTB4-E4)
BLT1, BLT2 (LTB4), CysLT1, CysLT2 (LTC4-D4)
?Gi/Go (BLT1,2, CysLT1,2), Gα16 (BLT1,2)
Leukocytes, spleen, thymus, bone marrow, lymph nodes, heart, skeletal muscle, brain and liver for BLT1, Most tissues for BLT2,
Coronary smooth muscle contraction, Transient pulmonary and systemic hypertension
1, 54
Gs, Tyrosine kinases, ERK1/2, p38 MAPK, Activation of Ca2+-activated K+ channels
Renal and cerebral vasodilation, Renal vasoconstriction, Vascular smooth muscle and endothelial cell proliferation
Role of sensory innervation in the cardiovascular system
Noxious stimuli are transduced by peripheral nociceptors, which transmit nociceptive information to pain processing centers in the brain via the spinal cord. Heart and blood vessels are densely innervated by sensory nerve endings that express chemo-, mechano-, and thermo-sensitive receptors, which include acid sensitive ion channels (ASIC), degenerin/epithelial sodium channels (DEG/ENAC), purinergic ATP gated ion channels (P2X), and transient receptor potential (TRP) channels [3–7]. Activation of nociceptive ion channels, particularly ASIC3 and TRPV1, has been implicated in ischemic cardiac pain [5]. Both these channels can be activated by acidic pH and sensitized by proinflammatory agents synthesized and/or released during ischemia.
Activation of Ca2+ permeant nociceptive ion channels on the peripheral and central terminals of sensory neurons leads to the synthesis and/or release of a variety of proinflammatory agents and neuropeptides, like bradykinin (BK), PGs, calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP) and adenosine triphosphate (ATP) etc. [8, 9]. Increases in intracellular Ca2+ initiate several second messenger pathways, including activation of PLA2, PLC and Ca2+-dependent kinases, which can lead to the generation of AA and its metabolites, release of Ca2+ from intracellular stores, and phosphorylation of nociceptive receptors, respectively. BK is thought to be synthesized and released on demand from sympathetic nerve endings [11]. BK initiates prostanoid synthesis and mediates release of vasoactive neuropeptides [10, 11]. PGE2 and PGI2 are produced in response to nociceptive stimuli and lead to inflammation and pain by sensitization of nociceptors. PGI2 is a potent vasodilator and platelet deaggregator [12]. In blood vessels, activation of nociceptive receptors results in an endothelium independent vasodilatory response, which is mediated mainly by the release of CGRP [13]. CGRP is a potent vasodilator (coronary vasculature is particularly sensitive) that increases both heart rate and contractile force [13, 14]. SP and VIP released from sensory nerve terminals induce vasodilation and positive chronotropic effect [15]. ATP is released ubiquitously along with neurotransmitters and induces vasoconstriction by activation of P2X receptors, however, its breakdown product adenosine is a potent vasodilator and also inhibits neurotransmitter/neuropeptide release [16]. Relatively less prominent vasoactive agents are also released from the nociceptive nerve endings including galanin, corticotrophin-releasing factor, arginine, cholecystokinin-octapeptide, neuropeptide K, eledoisin-like peptide and bombesin-like peptides [14]. Nociceptor stimulation not only serves as a sensory-afferent, but also plays a significant role in sensory-efferent functions [8]. It has also been postulated that vascular regulation via an efferent mechanism could be independent of the sensory afferent function [17] and the selective synthesis and/or release of specific vasoactive agents could arise from the nature of the stimulus and/or its intensity [18]. Thus, activation of Ca2+ permeable nociceptive ion channels at the peripheral and central terminals of sensory neurons can play an important role in the synthesis and/or release of vasoactive agents.
Nociceptive ion channels in cardiovascular system
Several nociceptive ion channels have been cloned. Most of these channels are modulated by PKA and PKC mediated phosphorylation. Significantly, PGE2 and PGI2 mediate their effects by activation of PKA and PKC pathways. The Transient Receptor Potential (TRP) channels (TRPVanilloid, TRPAnkyrin, TRPClassical, and TRPMelastatin) are chemo-, mechano-, and thermo-sensitive. TRPV1 is a well-characterized channel, which transduces heat in the noxious temperature range (>42°C) and is critical for inflammatory thermal sensation [19]. It is a Ca2+ permeant polymodal receptor activated by protons, anandamide, lipoxygenase metabolites of AA, N-arachidonyl dopamine, capsaicin (an active ingredient in hot chilli peppers) and resiniferatoxin (RTX, an ultrapotent agonist obtained from the cactus, Euphorbia resinifera) [20]. TRPV1 is distributed in the heart and blood vessels and is sensitized by PGs via PKA and PKC mediated phosphorylation [21]. Importantly, in the phosphorylated state, the activation threshold of TRPV1 is reduced below body temperature rendering the channel constitutively active [20]. Furthermore, phosphorylation also promotes translocation of TRPV1 from the cytosol to the plasma membrane [22, 23]. Activation of TRPV1 in sensory nerve endings supplying heart and blood vessels releases multiple vasoactive agents [14]. In diabetes, TRPV1 has been shown to be downregulated, which might contribute to the cardiovascular complications [23].
The role of TRPV1 in the cardiovascular system has been addressed: 1) Infusion of TRPV1 agonists significantly alters blood pressure, which could be mostly reversed by selective TRPV1 antagonists [24, 25]; 2) Ablation of TRPV1 expressing C fiber terminals by capsaicin or resiniferatoxin (RTX) results in the loss of CGRP release, increased plasma renin activity, and an inability to control salt loading by the kidneys [14]; 3) Activation of TRPV1 or ASIC3 by protons during ischemia mediates a sympathoexcitatory reflex that is abolished by RTX treatment [5, 26].
Inhibition of COX leads to increased metabolism of AA via LOX and CYP pathways. Products of LOX pathway (12- and 15-(S)-HPETE, 5- and 15-(S)-HETEs and LB4) can directly gate TRPV1 [20]. Myogenic constriction in response to increased pressure on the intraluminal surface of blood vessels is mediated by the CYP byproduct 20-HETE, which directly activates TRPV1 and releases SP [27].
We propose that reduction of PG levels may contribute to deleterious vascular effects by decreasing sensitization of TRPV1 and subsequent reduction of CGRP and SP release. This possibility is supported by the finding that recovery from myocardial ischemia is compromised in TRPV1 knockout mice [28] and proton mediated CGRP release from the heart is mediated exclusively by TRPV1 [29, 30]. Since TRPV1 antagonists may become a part of the therapeutic armamentarium for painful conditions [31], it is imperative to determine if blocking nociceptive receptors like TRPV1 decreases the release of vasoactive agents that are essential for homeostasis of the cardiovascular system.
TRPV2 is 50% identical to TRPV1 and mediates high-threshold (>52°C) noxious heat sensation. In arterial myocytes, TRPV2 is activated by stretch, which is an important stimulus in cardiovascular functions [32]. Cardiac-specific transgene expression of TRPV2 results in Ca2+-overload-induced cardiomyopathy [32]. TRPV3 is activated by temperatures >31°C and is involved in nociception [32]. TRPV4 is activated by temperatures >25°C and its activity is augmented by hypotonicity. PGE2 potentiates TRPV4 and exacerbates pain behavior in animals, whereas EET directly activates the channel [32, 33]. TRPV4 is found abundantly on endothelial and vascular smooth muscle cells of intralobar pulmonary artery and aorta where, it mediates calcium influx [34]. TRPM8 is a Ca2+ permeant innocuous cold temperature sensor, which plays a role in nociception [36] and mediates Ca2+ influx into vascular smooth muscle cells [34].
Mechanosensitive channels play a major role in cardiovascular functions and the identity of these channels is becoming apparent with cloning of TRPC1 and TRPA1 [32]. TRPC1, 2, 3, 4 and 6 are present on endothelial cells, activation of which increases intracellular Ca2+ [35]. DEG/ENAC belongs to a family of mechanosensitive channels, which include ASICs and their splice variants [37]. ASICs are modulated by AA, PKC and PKA [37–41]. ASIC1 behaves as a mechanosensor only in viscera, but not in the periphery [42, 43]. Activation of ASIC3 has been postulated to carry ischemic cardiac pain [5].
Chemo-sensitive purinergic receptors (P2X1–6) are activated by extracellular ATP. The P2X3 receptor subtype is expressed exclusively in small and medium diameter dorsal root and trigeminal ganglia neurons [44]. In the cardiovascular system, activation of P2X4 receptor increases cardiac contractility [45]. Activation of P2X mediates AA production via stimulation of PLA2 [46]. P2X1,2,7 channels are also regulated by PKC [47–49]. P2X1 is present on vascular smooth muscle cells and mediates vasoconstriction by ATP released from sympathetic nerve activity [50].
Advantages and disadvantages of selective inhibition of COX2
Although COX2 inhibitors have become popular, their analgesic effects are comparable to non-specific COX inhibitors [51]. The selectivity of COX2 inhibitors has a significant advantage of avoiding gastrointestinal side effects (VIGOR study) due to the preservation of PGE2 levels and a reduction in the incidence of colon cancer by inhibition of PG-mediated angiogenesis [52–54]. The inducible nature of COX2 is claimed to have significant advantages because it is activated only at the sites of inflammation. In this regard, it is significant to note that atherosclerotic lesions are inflammatory in nature [55] and PGI2 (vasodilator, platelet deaggregator and sensitizer of nociceptive receptors) is synthesized via COX2 activation as a necessary protective mechanism. Nonspecific COX inhibitors decrease production of both, PGI2 and TxA2 (platelet aggregator), thereby avoiding an imbalance between PGI2 and TxA2 levels [56]. In contrast, when COX2 is inhibited selectively, platelet aggregation by TxA2 is intact, but at the same time PGI2 induced platelet deaggregation is compromised, resulting in enhanced platelet aggregation [57]. Here, we propose that inhibition of PGE2 and PGI2 could also reduce sensitization of nociceptors and compromise release of potent vasodilators in response to ischemia, which could be critical in reversing hypoperfusion in conditions like myocardial ischemia. Indeed, injury-induced platelet activation is enhanced in PGI2 receptor (IP) knock-out mice [58], whereas it is reduced in TxA2 receptor (TP) knock-out mice [58]. These findings are consistent with patients treated with COX2 inhibitors suffering from higher incidence of MI and stroke as compared to naproxen treated patients [53, 59, 60]. A combination of a COX2 and a low dose of COX1 inhibitors (for example, 80 mgs of aspirin) may be a beneficial strategy to prevent TxA2-mediated platelet aggregation. Furthermore, the need for platelet deaggregation becomes even more critical, given the lifetime risk of developing atrial fibrillation significantly increases over 40 years of age [61], which can initiate thromboembolism.
Concluding remarks and future directions
The beneficial effects of COX inhibitors are derived from their ability to inhibit synthesis of PGs. However, several important cardiovascular functions mediated by PGs are compromised, including direct vasodilation, vasoconstriction, and platelet aggregation/deaggregation. Herein, we propose that the ability of PGs to sensitize nociceptive ion channels involved in the release of potent vasoactive agents could also be compromised. A well-characterized receptor in this context is TRPV1, which is sensitized by PGs and its activation mediates the synthesis and/or release of vasoactive agents by virtue of its high Ca2+ permeability. TRPV1 is currently being pursued as a potential target for the next generation of analgesics [31]. Use of COX inhibitors should be dictated objectively by understanding the mechanisms by which cardiovascular complications are induced, instead of being swayed by emotional testimonies in congressional inquires. Drug industries would be better advised to invest in research rather than spending billions (3 billion in 2004) in advertising and direct marketing to patients. Judicious use of these drugs with open dialogue between drug industries, physicians and patients must be encouraged, so that all the parties involved can make an informed decision, fully aware of the consequences. Patients who are in the right category would benefit from these drugs, while sparing others who are at a risk for cardiovascular complications. This strategy/approach will also avoid expensive class action lawsuits and prevent driving the cost of medication higher; otherwise, patients who need the medication most may not be able to afford.
We thank Drs. Kevin Dorsey and Mary Pauza for the comments on the manuscript. This work was supported by a grant from National Institutes of Health (NSO42296; DK065742) to L.S.P.
Authors' Affiliations
- Bogatcheva NV, Sergeeva MG, Dudek SM, Verin AD: Arachidonic acid cascade in endothelial pathobiology. Microvasc Res 2005, 69: 107–127. 10.1016/j.mvr.2005.01.007PubMedView ArticleGoogle Scholar
- Koistinaho J, Chan PH: Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem Res 2000, 25: 645–651. 10.1023/A:1007559003261PubMedView ArticleGoogle Scholar
- McQueen DS, Bond SM, Moores C, Chessell I, Humphrey PP, Dowd E: Activation of P2X receptors for adenosine triphosphate evokes cardiorespiratory reflexes in anaesthetized rats. J Physiol 1998, 507: 843–855. 10.1111/j.1469-7793.1998.843bs.xPubMed CentralPubMedView ArticleGoogle Scholar
- Burnstock G: P2X receptors in sensory neurons. Br J Anaesth 2000, 84: 476–488.PubMedView ArticleGoogle Scholar
- Sutherland SP, Benson CJ, Adelman JP, McCleskey EW: Acid-sensing ion channel 3 matches the acid-gated current in cardiac ischemia-sensing neurons. Proc Natl Acad Sci USA 2001, 98: 711–716. 10.1073/pnas.011404498PubMed CentralPubMedView ArticleGoogle Scholar
- Snitsarev V, Whiteis CA, Abboud FM, Chapleau MW: Mechanosensory transduction of vagal and baroreceptor afferents revealed by study of isolated nodose neurons in culture. Auton Neurosci 2002, 98: 59–63. 10.1016/S1566-0702(02)00033-4PubMedView ArticleGoogle Scholar
- Ditting T, Linz P, Hilgers KF, Jung O, Geiger H, Veelken R: Putative role of epithelial sodium channels (ENaC) in the afferent limb of cardio renal reflexes in rats. Basic Res Cardiol 2003, 98: 388–400. 10.1007/s00395-003-0426-7PubMedView ArticleGoogle Scholar
- Maggi CA, Meli A: The sensory-efferent function of capsaicin-sensitive neurons. Gen Pharmacol 1988, 19: 1–43.PubMedView ArticleGoogle Scholar
- McDonald DM, Bowden JJ, Baluk P, Bunnett NW: Neurogenic inflammation. A model for studying efferent actions of sensory nerves. Adv Exp Med Biol 1996, 410: 453–462.PubMedView ArticleGoogle Scholar
- Seyedi N, Maruyama R, Levi R: Bradykinin activates a cross-signaling pathway between sensory and adrenergic nerve endings in the heart: a novel mechanism of ischemic norepinephrine release? J Pharmacol Exp Ther 1999, 290: 656–663.PubMedGoogle Scholar
- Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A: The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005, 99: 6–38. 10.1254/jphs.SRJ05001XPubMedView ArticleGoogle Scholar
- Narumiya S, FitzGerald GA: Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001, 108: 25–30. 10.1172/JCI200113455PubMed CentralPubMedView ArticleGoogle Scholar
- Brain SD, Grant AD: Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004, 84: 903–934. 10.1152/physrev.00037.2003PubMedView ArticleGoogle Scholar
- Wang DH: The vanilloid receptor and hypertension. Acta Pharmacol Sin 2005, 26: 286–294. 10.1111/j.1745-7254.2005.00057.xPubMedView ArticleGoogle Scholar
- Watson RE, Supowit SC, Zhao H, Katki KA, Dipette DJ: Role of sensory nervous system vasoactive peptides in hypertension. Braz J Med Biol Res 2002, 35: 1033–1045. 10.1590/S0100-879X2002000900004PubMedView ArticleGoogle Scholar
- Burnstock G: Vascular control by purines with emphasis on the coronary system. Eur Heart J 1989, 10: 15–21.PubMedView ArticleGoogle Scholar
- Holzer P, Maggi CA: Dissociation of dorsal root ganglion neurons into afferent and efferent-like neurons. Neuroscience 1998, 86: 389–398. 10.1016/S0306-4522(98)00047-5PubMedView ArticleGoogle Scholar
- Hua XY: Tachykinins and calcitonin gene-related peptide in relation to peripheral functions of capsaicin-sensitive sensory neurons. Acta Physiol Scand Suppl 1986, 551: 1–45.PubMedGoogle Scholar
- Julius D, Basbaum AI: Molecular mechanisms of nociception. Nature 2001, 413: 203–210. 10.1038/35093019PubMedView ArticleGoogle Scholar
- Caterina MJ, Julius D: The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001, 24: 487–517. 10.1146/annurev.neuro.24.1.487PubMedView ArticleGoogle Scholar
- Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga T, Narumiya S, Tominaga M: Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005, 1: 3. 10.1186/1744-8069-1-3PubMed CentralPubMedView ArticleGoogle Scholar
- Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A: Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004, 279: 25665–25672. 10.1074/jbc.M311515200PubMedView ArticleGoogle Scholar
- Van Buren JJ, Bhat S, Rotello R, Pauza ME, Premkumar LS: Sensitization and translocation of TRPV1 by insulin and IGF-I. Mol Pain 2005, 1: 17. 10.1186/1744-8069-1-17PubMed CentralPubMedView ArticleGoogle Scholar
- Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400: 452–457. 10.1038/22761PubMedView ArticleGoogle Scholar
- Ross RA: Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003, 140: 790–801. 10.1038/sj.bjp.0705467PubMed CentralPubMedView ArticleGoogle Scholar
- Zahner MR, Li DP, Chen SR, Pan HL: Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. J Physiol 2003, 551: 515–523. 10.1113/jphysiol.2003.048207PubMed CentralPubMedView ArticleGoogle Scholar
- Scotland RS, Chauhan S, Davis C, De Felipe C, Hunt S, Kabir J, Kotsonis P, Oh U, Ahluwalia A: Vanilloid receptor TRPV1, sensory C fibers, and vascular autoregulation: a novel mechanism involved in myogenic constriction. Circ Res 2004, 95: 1027–1034. 10.1161/01.RES.0000148633.93110.24PubMedView ArticleGoogle Scholar
- Wang L, Wang DH: TRPV1 gene knockout impairs postischemic recovery in isolated perfused heart in mice. Circulation 2005, 112: 3617–3623. 10.1161/CIRCULATIONAHA.105.556274PubMedView ArticleGoogle Scholar
- Pan HL, Chen SR: Sensing tissue ischemia: another new function for capsaicin receptors? Circulation 2004, 110: 1826–1831. 10.1161/01.CIR.0000142618.20278.7APubMedView ArticleGoogle Scholar
- Strecker T, Messlinger K, Weyand M, Reeh PW: Role of different proton-sensitive channels in releasing calcitonin gene-related peptide from isolated hearts of mutant mice. Cardiovasc Res 2005, 65: 405–410. 10.1016/j.cardiores.2004.10.013PubMedView ArticleGoogle Scholar
- Krause JE, Chenard BL, Cortright DN: Transient receptor potential ion channels as targets for the discovery of pain therapeutics. Curr Opin Investig Drugs 2005, 6: 48–57.PubMedGoogle Scholar
- Pedersen SF, Owsianik G, Nilius B: TRP channels: An overview. Cell Calcium 2005, 38: 233–252. 10.1016/j.ceca.2005.06.028PubMedView ArticleGoogle Scholar
- Alessandri-Haber N, Yeh JJ, Boyd AE, Parada CA, Chen X, Reichling DB, Levine JD: Hypotonicity induces TRPV4-mediated nociception in rat. Neuron 2003, 39: 497–511. 10.1016/S0896-6273(03)00462-8PubMedView ArticleGoogle Scholar
- Yang XR, Lin MJ, McIntosh LS, Sham JS: Functional Expression of Transient Receptor Potential Melastatin- and Vanilloid-Related Channels in Pulmonary Arterial and Aortic Smooth Muscle. Am J Physiol Lung Cell Mol Physiol 2006, 290: L1267-L1276. 10.1152/ajplung.00515.2005PubMedView ArticleGoogle Scholar
- Freichel M, Vennekens R, Olausson J, Stolz S, Philipp SE, Weissgerber P, Flockerzi V: Functional role of TRPC proteins in native systems: implications from knockout and knock-down studies. J Physiol 2005, 567: 59–66. 10.1113/jphysiol.2005.092999PubMed CentralPubMedView ArticleGoogle Scholar
- Premkumar LS, Raisinghani M, Pingle SC, Long C, Pimentel F: Downregulation of TRPM8 by Protein Kinase C-mediated dephosphorylation. J Neurosci 2005, 25: 11322–11329. 10.1523/JNEUROSCI.3006-05.2005PubMedView ArticleGoogle Scholar
- Waldmann R, Champigny G, Lingueglia E, De Weille JR, Heurteaux C, Lazdunski M: H(+)-gated cation channels. Ann N Y Acad Sci 1999, 30: 67–76. 10.1111/j.1749-6632.1999.tb11274.xView ArticleGoogle Scholar
- Baron A, Deval E, Salinas M, Lingueglia E, Voilley N, Lazdunski M: Protein kinase C stimulates the acid-sensing ion channel ASIC2a via the PDZ domain-containing protein PICK1. J Biol Chem 2002, 277: 50463–50468. 10.1074/jbc.M208848200PubMedView ArticleGoogle Scholar
- Berdiev BK, Xia J, Jovov B, Markert JM, Mapstone TB, Gillespie GY, Fuller CM, Bubien JK, Benos DJ: Protein kinase C isoform antagonism controls BNaC2 (ASIC1) function. J Biol Chem 2002, 277: 45734–45740. 10.1074/jbc.M208995200PubMedView ArticleGoogle Scholar
- Leonard AS, Yermolaieva O, Hruska-Hageman A, Askwith CC, Price MP, Wemmie JA, Welsh MJ: cAMP-dependent protein kinase phosphorylation of the acid-sensing ion channel-1 regulates its binding to the protein interacting with C-kinase-1. Proc Natl Acad Sci USA 2003, 100: 2029–2034. 10.1073/pnas.252782799PubMed CentralPubMedView ArticleGoogle Scholar
- Allen NJ, Attwell D: Modulation of ASIC channels in rat cerebellar Purkinje neurons by ischaemia-related signals. J Physiol 2002, 543: 521–529. 10.1113/jphysiol.2002.020297PubMed CentralPubMedView ArticleGoogle Scholar
- Drew LJ, Rohrer DK, Price MP, Blaver KE, Cockayne DA, Cesare P, Wood JN: Acid-sensing ion channels ASIC2 and ASIC3 do not contribute to mechanically activated currents in mammalian sensory neurons. J Physiol 2004, 556: 691–710. 10.1113/jphysiol.2003.058693PubMed CentralPubMedView ArticleGoogle Scholar
- Page AJ, Brierley SM, Martin CM, Martinez-Salgado C, Wemmie JA, Brennan TJ, Symonds E, Omari T, Lewin GR, Welsh MJ, Blackshaw LA: The ion channel ASIC1 contributes to visceral but not cutaneous mechanoreceptor function. Gastroenterology 2004, 127: 1739–1747. 10.1053/j.gastro.2004.08.061PubMedView ArticleGoogle Scholar
- North RA: Molecular physiology of P2X receptors. Physiol Rev 2002, 82: 1013–1067.PubMedView ArticleGoogle Scholar
- Mei Q, Liang BT: P2 purinergic receptor activation enhances cardiac contractility in isolated rat and mouse hearts. Am J Physiol Heart Circ Physiol 2001, 281: H334-H341.PubMedGoogle Scholar
- Lee YH, Lee SJ, Seo MH, Kim CJ, Sim SS: ATP-induced histamine release is in part related to phospholipase A2-mediated arachidonic acid metabolism in rat peritoneal mast cells. Arch Pharm Res 2001, 24: 552–556.PubMedView ArticleGoogle Scholar
- Boue-Grabot E, Archambault V, Seguela P: A protein kinase C site highly conserved in P2X subunits controls the desensitization kinetics of P2X(2) ATP-gated channels. J Biol Chem 2000, 275: 10190–10195. 10.1074/jbc.275.14.10190PubMedView ArticleGoogle Scholar
- Vial C, Tobin AB, Evans RJ: G-protein-coupled receptor regulation of P2X1 receptors does not involve direct channel phosphorylation. Biochem J 2004, 382: 101–110. 10.1042/BJ20031910PubMed CentralPubMedView ArticleGoogle Scholar
- Hung AC, Chu YJ, Lin YH, Weng JY, Chen HB, Au YC, Sun SH: Roles of protein kinase C in regulation of P2X(7) receptor-mediated calcium signalling of cultured type-2 astrocyte cell line, RBA-2. Cell Signal 2005, 17: 1384–1396. 10.1016/j.cellsig.2005.02.009PubMedView ArticleGoogle Scholar
- Vulchanova L, Arvidsson U, Riedl M, Wang J, Buell G, Surprenant A, North RA, Elde R: Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry. Proc Natl Acad Sci USA 1996, 93: 8063–8067. 10.1073/pnas.93.15.8063PubMed CentralPubMedView ArticleGoogle Scholar
- Lee Y, Rodriguez C, Dionne RA: The role of COX-2 in acute pain and the use of selective COX-2 inhibitors for acute pain relief. Curr Pharm Des 2005, 11: 1737–1755. 10.2174/1381612053764896PubMedView ArticleGoogle Scholar
- Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94: 3336. 10.1073/pnas.94.7.3336PubMed CentralPubMedView ArticleGoogle Scholar
- Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343: 520–1528. 10.1056/NEJM200011233432103View ArticleGoogle Scholar
- Romano M, Claria J: Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003, 17: 1986–95. 10.1096/fj.03-0053revPubMedView ArticleGoogle Scholar
- Ross R: Atherosclerosis – an inflammatory disease. N Engl J Med 1999, 340: 115–126. 10.1056/NEJM199901143400207PubMedView ArticleGoogle Scholar
- Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ: Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000, 102: 840–845.PubMedView ArticleGoogle Scholar
- Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999, 289: 735–741.PubMedGoogle Scholar
- Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296: 539–541. 10.1126/science.1068711PubMedView ArticleGoogle Scholar
- Couzin J: Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Science 2005, 307: 1183–1185. 10.1126/science.307.5713.1183aPubMedView ArticleGoogle Scholar
- Lenzer J: FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. Br Med J 2005, 330: 440. 10.1136/bmj.330.7489.440View ArticleGoogle Scholar
- Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ: Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110: 1042–1046. 10.1161/01.CIR.0000140263.20897.42PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


text:
Are you looking to while away a couple of hours with like-minded people who love all things cross-stitch and needlework??
The Presentation of the Pontypridd Centenary Banner to the Museum in 2011, which had taken 5 years to complete.
Join us for a friendly chat, a cuppa with biscuits all for £3.00 per week which also includes a raffle. We meet in the community rooms at Pontypridd Museum every Monday, on alternating afternoons and evenings 1-3 pm and 7-9 pm. For more information about the club please ring Sue Smith on 01443 408097.


text:
Bulgarian Kaftan
Catalogue ID: 691
Description Wool kaftan styled on those depicted in the Menology of Basil II, 10th C. This reproduction consists of a fulled wool outer layer, and a light weight wool lining. It has been machine sewn, with all the hems, collar, cuffs and strips having been hand sewn. It features cast bronze buttons from a 10th C find in the Ukraine .
Price $450.00 excluding GST (Non-Australian residents)
Price $495.00 including GST (Australian residents)


text:
142. William SMART was born on 21 Nov 1731 in Rudgwick Sussex. He was married to Mary WILLETT on 8 May 1752 in Wisborough Green, Sussex.(170)
143. Mary WILLETT
was born on 22 Dec 1733 in Horsham Sussex.
(171) She was baptized on 22 Dec 1733 in Horsham Sussex.
(172) The register clearly shows that Mary was six mnths old at baptism,
no explanation given. Children were:
71 i. Mary SMART.
Return to Table of Contents


text:
Here at DMS, we don't always get a chance to shine a light on the contributors working within our Photo Studio. You may not know it, but we work with an entire community of photographers, photo editors and photo auditors who help us ensure that every single piece of content we publish gets the best visual treatment possible.
These dedicated community members are the ones who take our amazing Studio articles and give them that extra special something in the form of visuals. So to recognize them for their amazing, behind-the-scenes work, we're happy to launch our first ever DMS Visual Community Awards.


text: A way to help each other out (ie. msg us if there's a raid. Lol). PM me ur line id here or in game so I can add u in the group chat. Ty ~ Btw, I post this for my guild members if they're looking for me... I welcome ppl that add me n pm me, but can't invite u to my guild group unless ur a member. >_<


text:
Our New 2" Receiver Shackle Made from 100% Solid Billet 6061 Aluminum. Great To Have anytime you wheel in mud, rocks or snow. No need to modify for a rear Shackle/Tow point. Work Load Rating: 9500lbs Weight: 1.7lbs Add our US Made 3/4" (7/8" pin) Shackle to insure your using a quality product. This shackle was used while designing the new mount to insure the best quality fit and function.
This product hasn't received any reviews yet. Be the first to review this product!
All prices are in USD.


text:
MMO and Gaming Blog from Tom Purdue. It's origins began in a journey through Wizard101 and grew to be much much more.
Tuesday, July 24, 2012
Where does one get Amber? Two sources. One is gardening. The other is a thick transmute receipe involving 5 Merle's Whiskers, 5 Amber Dust, 15 Sunstone, and 10 Golden Pearl . . . to one Amber.
I choose Gardening!
To those ends I've been growing a lot of King Parsely. My buddy Gary at work is doing that too. He made a good point that King Parsely was a good route to go because it's a crown plant that reseeds plentifully. In fact, you can get a couple reseeds from one King Parsely plant over the course of its life.
Here I am standing in front of my elder Parsley Patch this morning.
YAY! I pulled four Amber out of that elder harvest, and from what I understand . . . I'm lucky!
How do you guys get your Amber?
8 comments:
- Katherine Light said...
Red Bell Peppers! They don't reseed like KPs and they're pricey... but they're faster and I need somewhere to burn all my gold anyway, lol. 10 out of 12 towards my deer knight spell! :D
- 24/7/12 19:09
Where may I find the deer knight recipe and are there other vendors that have permanent spell recipes other than the one in Jade Palace of Mooshu?
- 25/7/12 00:55
Also, I have been getting my amber from White Tiger Lilies, just about from each elder harvest luckily. Will try the Red Bell Peppers which drop decently from Mirror Lake. And I will try King Parsley as well. Thanks you both for that information. Anything on getting Amber reagents help.
- 25/7/12 01:00
- Stingite said...
So this can be a bit tricky. You have to complete the quest "Where the Demons Dwell" in Avalon (in Dun Scaith) to get the NPC who sells the deer knight recipe to show up. His name is Grady. You also have to pay 60,000 gold for the recipe. So far Grady and Yan Kan Kook in MooShu are the only spell vendors in the game.
- 25/7/12 04:26
- Stingite said...
I hear White Tiger Lilies are the fastest, but I haven't tried Red Bell Peppers. Good tip from Katherine!
- 25/7/12 04:27
- MEGALUS said...
The Avalon spell recipe vendor is actually in the Wild. He is in the tower right behind the wildfire treants. It's not the tower with white in its name where you can find Cassie. It's the one before it, and yes, you have to fight the boss in the tower in order to get the vendor to appear.
- 25/7/12 05:50
- Unknown said...
I've had great luck with Red Bell Peppers. Deadly Ninja Figs are good too and you can buy them in Wintertusk. I'm not having very good luck with King Parsley. I harvest 20 elder yesterday and I didn't get any amber. White Tiger Lilies are great, but very hard to get.
- 25/7/12 07:20
- Goon said...
I'm not quite done with the Zafaria crafting quest, trying to craft the Avalon Ice Gear that gives insane amounts of resist.
- 25/7/12 12:59


text:
Skip to Main Content
Office Closure
County observes Memorial Day
Read On...
Doing Business
How Do I...
Departments H-Z
Prosecuting Attorney
About the Office
On the Record: December 2015
Baking for domestic violence awareness
Baking for domestic violence awareness
In recognition of Domestic Violence Awareness Month, the Pierce County Prosecutor's Office held its annual, office-wide bake sale in October. All proceeds were donated to the YWCA of Pierce County, which provides safe shelter and comprehensive services for survivors of domestic violence.
The funds raised during the bake sale will have an immediate impact on clients served at the YWCA. Survivors of domestic violence often need door lock changes, taxi rides, gas cards and bus tickets. Help like this in a time of crisis has proven to make a difference in the lives of those in need.
Man sentenced to 31 years in murder of fiance
County Council funds unit to fight property
Annual campaign underway to prevent impaired
Man sentenced to 47 years for home-invasion
Baking for domestic violence awareness
Slideshow Left Arrow
Slideshow Right Arrow


text:
|Posted on November 19, 2014 at 2:45 AM
Doctor Who Series 8
It's a new year of Doctor Who as we dive into the world of Series 8 starring Peter Capaldi and Jenna Coleman as The Doctor and Clara respectively. There's also a guy named Danny Pink who doesn't have a lot to do but he's around too. He's alright.
Anyways, with all the new stuff, there's a lot to talk about, but the best way to do it is to just dive into the episodes as our infamous Doctor is regenerated and his Tardis is spit out of a giant dinosaur in Victorian England...yeah welome to Doctor Who folks. Dinos in London with bad digestion. Here we go...
Deep Breath
I have to be honest, as far as "New Who" goes and from the few I've seen from the older series, the first episodes with a new Doctor really aren't all that great. Only Matt Smith's did I feel actually "work" in introducing him, new companions and a pretty cool monster on top of it. I have respect for the 9th Doctor's first episode, it had a lot it had to handle, but it's also really uneven and I didn't like Rose (and still don't) and well…at least it's not the 10th's introductory episode because that was just all-around awful and he was barely in it.
So me saying that I didn't like this episode is kind of par for the course. It is also uneven. It also has a very uninteresting villain. It also doesn't quite have the character chemistry down (and one might say that as far as The Doctor and Clara go, they don't find that chemistry until much later this series). As much as I liked the setting and seeing the old gang again, it never really works in terms of plot and only, barely, works in introducing the new Doctor.
Now Capaldi, in what little he has here, is pretty great. He has some memorable moments, two in particular: his self-discovery in the alleyway with a drunk and at the end as he quietly contemplates if he has to kill the villain or not and takes a drink. They set him up pretty well: he's not manic, he's not funny, he's darker and more brooding. As much as I like that for the rest of the series, and though this sets it up fine, he also doesn't quite fit here. They never do, though. There's too much to do and explain and to give exposition with a regenerated new character to really have anything interesting to say or do other than the basic information.
As a story, it just doesn't come together. It has a bunch of ideas but doesn't manage to weave them well. The characters have moments but they also don't feel entirely in-line here. It's exactly what I expected a first episode with a new Doctor to be because I've only seen one that actually works.
Final Rating: 2 out of 5
Into the Dalek
Now here we go. We're doing something new and different. We have more time with this new Doctor and get a better feel for him, which is great. This is kind of an old-school throwback episode, I found: The Doctor and a group of people go into a dangerous situation and they start dying one by one and he has to get them out of it.
I love the set up here, unlike the first episode which really didn't have one. I like we see more of the Doctor, this particular Doctor, and his mindset and train of thought. Oh, he's certainly different: more snarky, more cynical, the ego is still there but now isn't hidden by mania and fast-talking. We'll talk more about the Doctor specifically later, but at least, here, he actually has something to do.
Unfortunately the story just doesn't really work, particularly the solution to the problem of this Dalek and why it's even important or why the Doctor even wants to get involved if he's already gritting his teeth at the thought of doing anything.
And that's where we kind of get our first look into what this season of Doctor Who is going to be: this new Doctor versus everyone else. This season, as this will show, is about personal relationships and character development than it is adventures in time and space when we get the first look at the new relationship between The Doctor and Clara and introduce Danny Pink who seems like a likable enough guy but never really gets to a good point of being the next interesting second companion like a Rory. This episode, though, doesn't do the Doctor's misguided relationships well as more future episodes will show, but it's also a pretty harmless second episode that gives us a better looks into his mindset.
Final Rating: 2.5 out of 5
Robot of Sherwood
Ah, here's something a little lighter. The show needed it at this point. Badly. Robot of Sherwood isn't a very memorable episode, but it's used well in terms of pacing out this series so it's not a constant barrage of 12th Doctor Dark self-loathing egotistical junk. Oh, well actually that's here, but the tone is better. The "feel" of this episode, despite a problematic final 15 minutes or so, gives the sense it was a little more thought out and more interesting than the previous two. More importantly is that the character chemistry feels more on-point and interesting and the Doctor cracks a little wise when needed.
I suppose the only downside here, other than the silly ending as mentioned, is that there's a set up for a mystery and big reveal but it really never comes. Instead we get a rather dull robot story that the Doctor more or less "called" in the first ten minutes. Thankfully, the chmistry between Claray, The Doctor and Robin Hood, played wonderfully by Tom Riley, is more than enough to make this a passable episode despite being rathe unremarkable.
There's not much to say, really. The entire episode is rather straightforward and pretty harmless for the most part, the lighter touches are needed by this point and they work.
Final Rating: 3 out of 5
I'm not sure why Moffet insists we need to strengthen Clara's importance to Doctor Who lore more. I mean, she's already been there and done that. There was an entire arc with Matt Smith that was all about it, and this all feels completely pointless. Stuff like Listen could be good if the episode didn't insist on her value because everything up to the final scenes are some of the best Doctor Who stuff you could ask for in this episode.
Because Listen could have been great rather than just "pretty good."
The first thing to note here is the directing by Douglas Mackinnon. He dipped is toes in a few past Doctor Who episodes, but his work in Series 8, as will be shown, is fantastic. In fact, though I like the "lore" this episode weaves and the great performance by Capaldi, who really comes into his own as The Doctor here, I would say the way it is all directed and put together and shot is fantastic. It's dark. It's a little scary. It's also very patient with its actors.
Listen's story managed to do a lot in just an hour. You have a bit more Danny Pink and Clara stuff, you see the strain that Clara and the Doctor's relationship seems to be having as Clara, quite obviously, wants to have a different life than the one she's been thrust into - setting up her overall arc in the Series. Best of all is you have a unique mystery the Doctor obsesses in solving, something we haven't seen Capaldi do yet: be very "Doctor-y" in his desire for knowledge and figuring something out. There were hints, but here he's all-out seeking a truth.
Of course, is the big "reveal" at the end seems to fracture a lot of people about it. It's a big episode in that it's a very personal one for The Doctor. Again, this is another Moffat script that starts incredibly well but simply doesn't know how to end and wrap it up. There is so much good in the episode that the reveals and how its all handled makes this disappointing. What works really works, but what doesn't really doesn't.
Final Rating: 3.5 out of 5
Time Heist
There's probably a really good Doctor Who episode here in Time Heist. Somewhere. It has the set up and it has the elements: Clara and the Doctor are forced to team up with to strangers with unique abilities to rob a bank while having a time-travel twist. That sounds like a helluva pitch if you ask me.
But something happened that is hard to really nail down. The script isn't as nearly as clever as it thinks it is, and it never really nails its reveals as sharply as it should. In fact, the entire reveal of what is actually happening is a predictable one, and there's not enough of an emotional core or character stuff, as some of the other weaker-plot episode have, to really lift it up.
So we're left with a lot of mediocrity. I think director Mackinnon here again does the best he can, but something isn't clicking on the story and plot level much in the same way it didn't click with Into the Dalek. The Doctor, also, seems to have taken a step back as a developing character here. HIs motivations just doesn't gel with what the entire Series 8 had been working with thus far.
Time Heist is wasted potential with little to work with. It's not the worst episode of this Series, however.
Final Rating: 2 out of 5
The Caretaker
This and the following episode seem to be pretty devisive, and it's easy to see why. Both start strong and both end poorly. Thankfully, both have some great character stuff that really works to their benefits. Here, it's a little lighter. After the melodrama of Time Heist and before the serious tone of Kill the Moon, it's nice to have a little lighter story.
And best of all is this is the first time I really, really loved Capaldi's work. He was also good in Listen, but it was lost underneath all the plot. Here it's straightforward and entirely on his shoulders, and he really makes it work. In fact, every episode from here on out his Capaldi really as his character. He's top-notch for the final half. Yes, even that awful episode we have yet to get to. You can see him working his character up to this point, but here it all really seemed to come together as we get it front and center.
The Caretaker takes place on present day Earth, and I always enjoy those. I think it's because it's easier to relate to than the fantasy and sci-fi elements of going to other times and planets. Here it's all familiar, and maybe that comfort level is why everyone seems to have their A-game on. The Caretaker is a more irreverent and light episode as The Doctor tries to solve a mystery while pretending to be the Caretaker (janitor) as Clara's school.
Of course the plot still kind of gets away from it here, but all the Doctor-Clara-Danny dynamic works…until the end.
The Caretaker could have been a great episode, but for some reason we have a really weird ending here that, as seems to be the case this year, makes it all underwhelming and dissatisfying. They trick the monster by working together, but it's all so stilted and contrived, and it has Danny doing a really awkward flip that feels so out of place…something just doesn't really work in this scene and maybe it was the bad writing all along, or the director didn't know how to shoot it. It's messy.
It does end on a stronger note, though, with again the Series 8 strength: character development. We get the first indication that Clara and The Doctor's relationship is strained because Danny Pink flat-out calls The Doctor out on his bullshit. And that's going to make waves to…
Final Rating: 3.5 out of 5
Kill The Moon
Oh Kill the Moon. I don't know a lot about Peter Harness, the man who wrote this one, nor do I know a lot about the director, Paul Wilmshurst. What I do know is that Kill the Moon doesn't work. It just doesn't.
Initially I was fine with it. Sure, the heavy-handed metaphor about women's rights and abortion was like a sledgehammer to the temple, but Doctor Who has done that before with its themes and messages so I was fine with it. But man, it just gnawed at me over time because there's a lot I want to like about Kill the Moon but actually loathed the more thought put on it.
For starters, the setting. I love isolated space stuff with suspense. Some of my favorite Doctor Who episodes like Waters of Mars and The Satan Pit come to mind. I also loved Capaldi here, who shows that dark edge that we've seen throughout (sans Time Heist) and really puts it all on Clara's shoulders. I liked that too because that leads to Clara confronting The Doctor on his BS and nobody has really done that for the most part.
I mean, The Doctor has always treated humanity both with love but also with a bit of contempt. He's always had an ego. He's always never full "gotten" interpersonal relationships, and this calls him out on it. Of course, it did mean he did a very un-Doctory thing to make it happen, and that's why this one, like The Caretaker, is so devisive. You already had the unsubtle themes, now you have The Doctor forcing Clara to make a choice. That's…kinda shitty.
I love she called him out on it. Seriously, Jenna Coleman sells the hell out of that, but it means he had to do something pretty awful. Is that worth sacrificing? He's a darker, certinaly more cynical Doctor but he would never sit there and say "well, good luck. See you later."
It's a tough call, but I'm willing to let it slide. I won't let slide, however, the dumb ending and lack of subtle themes. Those were just way overboard, so we end up with a middle-of-the-road episode that had some great moments here and there with its failings in its final Act.
Final Rating: 3 out of 5
Mummy on the Orient Express
Oh, thank God. Finally I can type about the first legitimately great episode of the series.
That's not to say I haven't been enjoying it so far. It's simply been inconsistent. The actors have all been great, but the writing has been pretty much all over the map. Mummy on the Orient Express, from top to bottom, just feels so refined and polished and well done that it is one of the reasons Series 8 wasn't a complete dull experience. Written by Jamie Mathieson, who also wrote the best episode of the season (coming up), we have a classic Doctor Who set up: Doctor and Companion arrive someplace with some interesting characters and bad things start happening.
No big "reveal" or needing some big "twist" where you write yourself into a corner, it's all pretty straightforwrad and relies on character chemistry and solid acting. That's great Doctor Who in my book. Mummy on the Orient Express is just a wondefully fun yet sincere little episode that doesn't try to be too big and settles firmly on solving a mystery. This mystery, amazingly, doesn't let you down. It all builds and builds to a great reveal and ushers in one of the best Doctor Who writers that I hope will stay around for more to come.
And boy is Capaldi great in this episode. Even better is that it asks big questions about The Doctor. No, not "lore" or "history" but who he is as a person: the entire crux of Serial 8 in a nutshell. Does he care that people are dying? Is he willing to sacrifice? Is he just toying with us because of his own curiousity?
That's some big stuff but all done so subtly and intimatly that it makes me wish every episode was like this. It's a taught and suspenseful episode that literally has a ticking clock but manages to have wonderful character stuff with The Doctor and the passengers on the train - it's a great balance and, honestly, how Doctor Who episodes should be. That and the next one, that is.
Final Rating: 4 out of 5
Flatline is nearly a perfect Doctor Who episode. Seriously. And it doesn't even have a ton of The Doctor in it. It's is like a person you're dating: it starts great, builds up wonderfully, then the next thing you know you're having awesome sex.
Ok, that's a horrible analogy, but that's the sense of great pacing and ultimate satisfaction put into this second episode written by Jamie Mathieson. It's a great script with the characters at their very best and it brings in a unique monster into the mold and does some very creative and inventive things we really haven't seen yet.
First, Clara is center stage. Now by this point we can all agree that Clara's tale is pretty much over and her being in Series 8 is more for a transition reason than a story one. She's fine, but her arc as the "Impossible Girl" under Smith's tenure is told and done and there's really not a whole lot else for her to do. Well, they found her something to do by midway of this Series and especially in this episode (the next few episodes not so much but we'll get to them). Here she has to, essentially, "be" the Doctor. She has to think on her feet and act as he does.
Capaldi is almost entirely in the every-shrinking Tardis (shrinking on the outside because physics, I suppose). Capaldi alone on the Tardis being The Doctor is an absolute joy. From this little "gimmick" of the shrinking Tardis, we have a ton of puns and jokes and sight gags that feel so natural and funny despite the serverity of the situation at hand. From the "Two-Dis" device to Clara magically pulling a sledgehammer out of her purse to the Tardis being "cute" as she lugs it around. The interplay between her and the Doctor in this manner has shown that the chemistry between Jenna Coleman and Peter Capaldi is terrific as they really don't even spend a lot of time in the same shot. It's just sharp writing and great dialogue between them.
Then you have the uniqueness of the monster themselves. Flatline plays with perspective and expectations and toys with your mind, and that genius falls not only on the writer who had to think of it, but on the visual direction and special effects as well. A simple pan on a wall changes your perspective and completely messes with your head as everything is "flat" and "2D."
So, not only do you have a solid story, good character chemistry and a great hook, you have one of the most visually interesting Doctor Who episodes of recent memory.
And best of all…it's fun. I mean, a lot of fun. Mummy on the Orient Express had a bit of fun, but not nearly as much as this one yet still manage to keep it all with a level of sincerity. Look how much fun The Doctor is having.
This is the first time we really see him like this…
Oh, it's still The Doctor being all pissy for the most part, but those little flashes and the interplay between Coleman and Capaldi really round the whole thing out for him. He's having fun. We're having fun. This is the most fun I've had with Doctor Who for a long time.
Final Rating: 4.5 out of 5
In the Forest of the Night
If everyone pretty much agreed that Mummy and Flatline were the strongest of the season, everyone also seems to be in agreement that In the Forest of the Night is the worst. In fact, it's one of the worst of any Doctor Who episodes or serials because of many reasons. For one, it's filler. Obvious filler. It wants to be character-centric but it really doesn't have anything interesting to say about the characters and nothing really interesting for them to. There's an occasional moment here and there but overall it never does anything with them
For two: kids. Kids on Doctor Who rarely work, if ever. Sometimes its the actors, but really its just the way they're written. They're either super obnoxious and invasive to the story or they just add absolutely nothing at all to even being there. Usually both. Here they're both.
For three: there's a forced "meaning" to the plot here that never works and you think it might do something interesting with the characters, but then it brings in the forced resolution that pretty much undermines it all. And it's a poor resolution, folks. Oh man. "The kid has powers" is all it ends up being and everyone works together to tell the rest of the world (the world) to not hurt the trees.
For four: That last part above about the trees? Boy, that's as heavy-handed as Kill the Moon's abortion. Already forced into the story, it's also very, very heavy on repeating that fact. Subtlety was not the strong suit of this and the previous episode, which is too bad because, conceptually, they might have been cool. They just didn't have the story to go with it. Here it's with an environmental message that tries to make a big, soapbox point but, again, it can't do it if it doesn't have a story. At least Kill the Moon had a story and a concept, this episode is, literally "walk around and talk a lot, oh and there are some wolves for five seconds to inject at least a little bit of conflict."
There's a couple of spots of good character stuff, notably with Danny Pink/Clara (Clara, in particular, is kind of bad this episode however as she seems to have backtracked from the development of Kill the Moon), but it all becomes kind of lost. Oh, and one more thing on the kids. Look, they've been kind of around all along in Series 8 but they're intrusively bad here. I don't know why, but Doctor Who cannot do kids well. In an episode already full of problems and where very little actually happens, having them constantly be stupid didn't help.
Final Rating: 1.5 out of 5
Dark Water //Death in Heaven
So basically the whole Clara saying "I'm the Doctor" was only there to be in the trailer, because you know what happens with that?
Nothing. At all. It's never mentioned again…
And that's what's wrong with Death in Heaven and Dark Water. When it's with Capaldi, it's great. When it's trying to throw other stuff in that we, quite honestly, don't give a second thought about, it's rough. Hard to watch, even. It's bad enough it's just another Cybermen story, which we just had at the end of the previous Series, but it also undermines the one other good thing about this two parter...
No, not in-jokes.
Ah, there we go.
The story is poor, but boy does Missy make it fun and interesting. We've seen her in spots throughout, but here we get the full reveal, which most called, and Michelle Gomez is just fantastic as her. In fact, what Capaldi is with restraint and small flashes, Gomez is with unrelenting insanity. She is having fun. The writers are certainly having fun with her. In fact, she pretty much makes the finale watchable.
Because when she or Capaldi aren't around, this two-parter is pretty damn awful. For starters, the reveal and motivations are never clear for Missy or her purpose. She "wants her friend back" yet that sudden approach seems to come out of left field. Then she has this thing with a bracelet that can control all the cybermen except two because...well because the plot says so I suppose...and then you have this overlong, overly-melodramatic-even-for-Doctor-Who-standards finale in a graveyard where a lot of people say stuff then they don't and the Brigadier shows up and gives a salute.
If it sounds I'm completely disinterested in this episode, it's becaues I was and I am. Like many of the even the bad episodes, there are flashes of really great stuff happening, but it's just a hot mess of over indulgence - something Series 8 really hadn't done since the first episode to be honest (and something very much because of Moffat's insistence to start and end "big").
While it was nice to see a few characters back, though briefly, and that all the Doctor's doings in the past have actually led to something in terms of his place on Earth, it all feels so matter-of-fact whereas everything with Danny and Clara is never really set up well and certainly not ended well.
Actually, Danny's journey never really feels complete. He kind of just "was" and despite a lot of stuff written about him, and his family, in one episode, you're not going to be feeling much for Clara and him when the ending starts kicking into gear. It's like it's telling you this is emotional but it doesn't feel that way.
So that's the finale...kind of a cold, uninspired end that is dissapointing because the series really needed to finish strong. It had some great moments here and there, but not enough of a complete package. At least Missy and The Doctor keep it all interesting.
The Series Overall
Series 8 had more hits than misses, but there's no denying that the misses are big-time misses. I feel we saw one of the very best Doctor Who Episodes this year but also one of the worst. Everything else kind of fall sin the middle and doesn't really offer much outside of fleshing out Capaldi's Doctor (see below) and the character interaction.
The characters were the strength. Yes, even Danny Pink because we kind of need that "anchor" to reality even if he didn't have a ton to do. The format was what I found most interesting. While there is an "overarching" story, it's done it small bits until the two-part finale. There's not constant narrative and we're given a lot of one-shot episodes that Moffat and company kind of adopted during the first part of Series 7 only done far better here.
That's a good thing, because when you have standalone stories not bowing to needing to explain the larger story, you have episodes like Blink or Flatline. As good as Matt Smith was, the writing often just got ahead of itself and never ended up going anywhere. A lot of buildup. A lot of promise. A lot of "that's it?"
So, in terms of structure and pacing out this series, it was all solid with good variety and not having to be beholden to the whole Missy/Nethersphere/Dark Water/Cyberban fiasco we end on.
That being said, as is often the case lately with Doctor Who, the standalone stories kind of write themselves into a corner and never quite end as well as they begin. Time Heist, for example, was a really cool idea completely fumbled and Deep Breath was a dull and strangely paced debut - not as bad as David Tennent's first episode but nowhere as good as Smith's. Kill the Moon was another that had a ton of potential that never really went anywhere, The Caretaker did the same as well as it ended on a dull note and the finale was just a melodramatic mess that made little to no sense whatsoever.
Now "not making sense" is a Doctor Who staple, but here it's more apparent because we linger on it for so long. I mean, the final 20 minutes of "Death in Heaven" was damn-near unwatchable. Thankfully we see an angry Doctor, which I loved:
And in a way that anger kind of reflects my own view of the entire Series 8. It was frustrating. The Doctor and Clara were great, there were some inventive and interesting things happening, but overall the Series was let down by mostly mediocre writing and an uninspired finale. It was saved by Capaldi more than anything because...
The Doctor Overall
After the three Doctors that, more or less, shared a lot of traits, we needed a shakeup. We needed something new. The first bit: making the Doctor older. Great choice. That gets a lot of stuff out of the way (The Doctor being over sexualized a major one). The next bit: write darker. Less mania, less fluttering about the Tardis with catch-phrases and winks. It was time for something different…and this shot kind of sums that up perfectly:
"I've got the horrible feeling I'm going to have to kill you. Thought you might appreciate a drink first. I know I would."
There's something mature about that - something different. The show set the stage early and, mostly, stayed true to this new mature and adult Doctor. He's not "darker" per se, he's just less juvenile. More Serious. More sincere about who he is as a person than simply wizzing off to adventures.
Now I'm not a big Who Historian or anything, but I do know that this is more of a throwback than it is something "new." Because Doctor Who is so reactionary, or was, in regards of its Doctors from one to the other, it's interesting to see the stark contrast from Matt Smith to Peter Capaldi and the reaction of fans who never experienced it. I've only read about the changes from the grounded and antagonistic Pertwee era to the looney Baker era then to Davison who's fifth Doctor was extremely empathetic.
Capaldi is a reaction to the previous three Doctors on the "New Who" era, and it's what the series needed. The final season or so of Matt Smith was just not working. There were some great stuff, don't get me wrong, but a lot of run-of-the-mill stories that really didn't do anything interesting and the "Impossible Girl" arc just never landed right with me. I think there's some cool episodes, certainly, but that overarching plot and the over-importance of Clara as some "savior" was just overwrought and, as usually with Moffat, overwritten.
So we pull it back, let it settle in, and we end up with a Doctor who seems like he would roll his eyes at the sheer thought of going overboard with stuff. And Series 8 never really does that. It shows more restraint even when if writes itself into a corner. The only "big" episodes were the first and last three while everything in between seemed to be on a solid level of just trying to tell good stories.
The Doctor during all that kept it cool and precise. Never too personal, but there was always something underneath those old eyes. Capaldi gives a layered, nuanced approach - only revealing bits and pieces of an angry man or a sad man or even a happy man. This Doctor is more bold, takes more risks, but also cares. The problem is that he doesn't want to show it. He doesn't want to get "attached" anymore and go through having to leave a companion in another dimension or time or have their memories scrambled.
And that's why the final scene with his goodbye to Clara is so damn good. It's perfect and sums it all up nicely. We saw the darkness and seriousness early on, as he tells who he is is:
And we see the final reasoning behind all that with this:
That's an arc worth applauding. That's a Doctor and performance worth applauding even if the scripts and plots weren't up to the level of the charactel. Capaldi elevated a lot of mediocrity this season and his chemistry with Coleman, and the exploration of The Doctor and his realtionship to Clara and other people, is the high point of a solid but not a "wow" first Serial for a new era. Thanks to Capaldi, though, I'm excited in the direction it could hopefully go in the future.
Categories: None
Oops, you forgot something.
The words you entered did not match the given text. Please try again.


text:
HPV infection is the most common cause of an abnormal Pap test. Precancerous changes on the cervix caused by HPV and picked up by the Pap test account for 300,000 new cases of high-grade precancer dysplasia per year, and another 1.4 million new cases of low-grade precancer annually. In addition, there are approximately 1 million new cases of genital warts diagnosed each year.
Gardasil® (Quadrivalent Human Papillomavirus [types 6, 11, 16, 18] Recombinant Vaccine), the vaccine currently available to prevent HPV infection, renders protection against the HPV virus types 6,11,16, and 18, which covers the most common types involved in cancer, precancer, and wart lesions. This vaccine is currently approved for girls and women ages 9 to 26 years. Studies are underway to secure approval for older women and males.
These viruses are very easily acquired. By age 50, at least 80 percent of women will have acquired a genital HPV infection. Transmission through intercourse is most common, but many experts feel that the virus can be carried from one partner to another by fingers, sex toys, and other objects. It is highly infectious and very prevalent, especially among 15 to 24 year olds, where it is estimated that 9 million are currently infected in the United States. In studies of women 25 years of age and younger, prevalence rates range from 28 to 46 percent.
The HPV vaccine is manufactured from the protein capsule of the viral particle grown in yeast cells and contains no viral DNA and RNA, so there is no danger of transmitting the disease with the vaccine. The vaccine does contain an aluminum salt as an adjuvant, and rare allergies to this substance have been reported. In general, the vaccine is very safe and highly effective when administered in three doses over a six-month period. Each 0.5 ml dose is given into a limb muscle.
Gardasil should be given to all girls and women regardless of previous sexual activity or documented HPV infections. Females who have already been infected with one of the four viral subtypes contained in the vaccine can be protected against those subtypes to which they have not been exposed. The earlier in life the vaccine is administered, the better the immune response as measured by studies of antibody levels. Timing of doses is somewhat flexible, allowing for college holidays and other commitments.
The cost of the vaccine alone is approximately $150.00 per dose or $450.00 for three doses. When a girl or woman is within the CDC-approved age group of 9 to 26 years, most health insurance plans cover the cost. The vaccine is contradicted in patients allergic to yeast or aluminum and it is also not administered in pregnancy.
Information on whether or not a "booster shot" will be necessary in the future to maintain immunity has yet to be determined. Studies out as long as seven years have not indicated such. Hopefully, the studies being done on males will be adequate so they too can be immunized. As always, consult your physician if you have questions.
The Gynecologic Oncology Group—a national non-profit organization dedicated to promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies—offers answers to important questions concerning gynecologic oncology. For more information, visit www.gog.org.
Copyright © 2010 CancerConsultants Cervical Cancer Information Center. All Rights Reserved.
Tags: Cervical Cancer, Uncategorized